Gumisad, Rhisalyn C.

HRN: 21-66-74  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/10/2022
CEFUROXIME 1.5GM (VIAL)
07/10/2022
07/10/2022
IVTT
1.5
On Call To OR
For Stat CS
Waiting Final Action 
07/11/2022
CEFUROXIME 1.5GM (VIAL)
07/11/2022
07/13/2022
IV
1.5g
Q8
S/P CS
Waiting Final Action 
07/11/2022
CEFUROXIME 500MG (TAB)
07/11/2022
07/16/2022
ORAL
500mg
BID
Status Post CS

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: